Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa

被引:11
作者
Kana, Bavesh D. [1 ]
Arbuthnot, Patrick [2 ]
Botwe, Benjamin K.
Choonara, Yahya E. [3 ,4 ]
Hassan, Fatima [9 ]
Louzir, Hechmi [10 ]
Matsoso, Precious [5 ]
Moore, Penny L. [6 ,11 ,12 ]
Muhairwe, Apollo [13 ]
Naidoo, Kubendran [2 ]
Ndomondo-Sigonda, Margareth [3 ,14 ]
Madhi, Shabir A. [7 ,8 ]
机构
[1] Univ Witwatersrand, Natl Res Fdn, Dept Sci & Innovat, Ctr Excellence Biomed TB,Fac Hlth Sci, Johannesburg, South Africa
[2] Univ Witwatersrand, South African Med Res Council Antiviral Gene Ther, Fac Hlth Sci, Johannesburg, South Africa
[3] Univ Witwatersrand, Wits Adv Drug Delivery Platform Res Unit, Dept Pharm & Pharmacol, Fac Hlth Sci, Johannesburg, South Africa
[4] Univ Witwatersrand, African Network Drugs & Diagnost Innovat Ctr Exce, Fac Hlth Sci, Johannesburg, South Africa
[5] Univ Witwatersrand, Hlth Regulatory Sci Platform, Wits Hlth Consortium, Fac Hlth Sci, Johannesburg, South Africa
[6] Univ Witwatersrand, South African Med Res Council Antibody Immun Res, Fac Hlth Sci, Johannesburg, South Africa
[7] Univ Witwatersrand, South African Med Res Council Vaccines & Infect D, Fac Hlth Sci, Johannesburg, South Africa
[8] Univ Witwatersrand, African Leadership Vaccinol Expertise, Fac Hlth Sci, Johannesburg, South Africa
[9] Univ Cape Town, Hlth Justice Initiat, Sch Publ Hlth & Family Med, Cape Town, South Africa
[10] Univ Tunis El Manar, Inst Pasteur Tunis, Lab Transmiss Control & Immunobiol Infect LR11IPT, Tunis, Tunisia
[11] Natl Inst Communicable Dis, Johannesburg, South Africa
[12] Natl Hlth Lab Serv, Johannesburg, South Africa
[13] Natl Drug Author, Kampala, Uganda
[14] African Union Dev Agcy New Partnership Africas De, Midrand, South Africa
关键词
NEUTRALIZING ANTIBODIES; SYSTEM; VIRUS; DELIVERY; IMMUNITY; IMMUNOGENICITY; SEROTYPE-5; EFFICACY; MUCOSAL; FUTURE;
D O I
10.1016/S1473-3099(22)00878-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The COVID-19 pandemic heralded unprecedented resource mobilisation and global scientific collaboration to rapidly develop effective vaccines. Regrettably, vaccine distribution has been inequitable, particularly in Africa where manufacturing capacity remains nominal. To address this, several initiatives are underway to develop and manufacture COVID-19 vaccines in Africa. Nevertheless, diminishing demand for COVID-19 vaccines, the cost competitiveness of producing goods locally, intellectual property rights issues, and complex regulatory environments among other challenges can undermine these ventures. We outline how extending COVID-19 vaccine manufacturing in Africa to include diverse products, multiple vaccine platforms, and advanced delivery systems will ensure sustainability. Possible models, including leveraging public-academic-private partnerships to enhance success of vaccine manufacturing capacity in Africa are also discussed. Intensifying research in vaccine discovery on the continent could yield vaccines that further bolster sustainability of local production, ensuring greater pandemic preparedness in resource-constrained environments, and long-term health systems security.
引用
收藏
页码:E288 / E300
页数:13
相关论文
共 108 条
  • [1] Inequitable COVID-19 vaccine distribution and the intellectual property rights prolong the pandemic
    Altindis, Emrah
    [J]. EXPERT REVIEW OF VACCINES, 2022, 21 (04) : 427 - 430
  • [2] Africa is bringing vaccine manufacturing home
    不详
    [J]. NATURE, 2022, 602 (7896) : 184 - 184
  • [3] [Anonymous], 2021, LANCET, V397, P941, DOI 10.1016/S0140-6736(21)00617-6
  • [4] [Anonymous], 2020, VOA NewsJuly 14
  • [5] [Anonymous], 2022, FAQ-The mRNA Vaccine Technology Transfer Hub
  • [6] Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity
    Bakke, H
    Samdal, HH
    Holst, J
    Oftung, F
    Haugen, IL
    Kristoffersen, AC
    Haugan, A
    Janakova, L
    Korsvold, GE
    Krogh, G
    Andersen, EAS
    Djupesland, P
    Holand, T
    Rappuoli, R
    Haneberg, B
    [J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2006, 63 (03) : 223 - 231
  • [7] Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis
    Barber, Ryan M.
    Sorensen, Reed J. D.
    Pigott, David M.
    Bisignano, Catherine
    Carter, Austin
    Amlag, Joanne O.
    Collins, James K.
    Abbafati, Cristiana
    Adolph, Christopher
    Allorant, Adrien
    Aravkin, Aleksandr Y.
    Bang-Jensen, Bree L.
    Castro, Emma
    Chakrabarti, Suman
    Cogen, Rebecca M.
    Combs, Emily
    Comfort, Haley
    Cooperrider, Kimberly
    Dai, Xiaochen
    Daoud, Farah
    Deen, Amanda
    Earl, Lucas
    Erickson, Megan
    Ewald, Samuel B.
    Ferrari, Alize J.
    Flaxman, Abraham D.
    Frostad, Joseph Jon
    Fullman, Nancy
    Giles, John R.
    Guo, Gaorui
    He, Jiawei
    Helak, Monika
    Hulland, Erin N.
    Huntley, Bethany M.
    Lazzar-Atwood, Alice
    LeGrand, Kate E.
    Lim, Stephen S.
    Lindstrom, Akiaja
    Linebarger, Emily
    Lozano, Rafael
    Magistro, Beatrice
    Malta, Deborah Carvalho
    Mansson, Johan
    Herrera, Ana M. Mantilla
    Mokdad, Ali H.
    Monasta, Lorenzo
    Naghavi, Mohsen
    Nomura, Shuhei
    Odell, Christopher M.
    Olana, Latera Tesfaye
    [J]. LANCET, 2022, 399 (10344) : 2351 - 2380
  • [8] Basta NE., 2020, COVID-19 Treatment and Vaccine Tracker
  • [9] Beukes S., 2022, Aspen concludes agreement to manufacture and make available an Aspen -branded COVID-19 vaccine (Aspenovax) throughout Africa
  • [10] Moving beyond traditional valuation of vaccination: Needs and opportunities
    Bloom, David E.
    Brenzel, Logan
    Cadarette, Daniel
    Sullivan, Jessica
    [J]. VACCINE, 2017, 35 : A29 - A35